EUVIMEDEUVIMED entdecken
Crossref

Current use of proton pump inhibitors and when to limit, stop or not start treatment

Holmfridur Helgadottir, Einar Stefan Bjornsson

Læknablaðið · 06.07.2023 · 109 (0708) · 338-345

DOI: 10.17992/lbl.2023.0708.752 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Læknablaðið, online erschienen am 06.07.2023. Verfasst von Holmfridur Helgadottir und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Haraldsplass Diaconal Hospital, Bergen, Norway, 2Department of Gastroenterology, Haukeland University Hospital - Ber…. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori, Gastroesophageal Reflux.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proton pump inhibitors (PPIs) are potent inhibitors of gastric acid secretion that have changed treatment practice for gastric acid–related disorders. The major adequate indications for their use are treatment of gastro-esophageal reflux disease, peptic ulcers, eradication of Helicobacter pylori infection in combination with antibiotics and prophylaxis for patients on non-steroidal anti-inflammatory or antiplatelet drugs. Since their introduction, clinical success has been accompanied by widespread use of PPIs, which has steadily increased over the last decades without concomitant increase in the incidence of acid-related disorders. PPIs are now among the most widely prescribed class of medications worldwide and around 10% of Icelanders are current PPI users. This increase has been linked to PPI prescription without an indication, or continued use for longer duration than recommended. In recent years, concerns have been raised about PPI overuse and the associated increased risk of harm, not only in terms of increased costs but also the potential risk of physical dependence and long-term side effects of PPIs. The article is based on search in PubMed, the authors’ own clinical experience and research, and is intended to provide practice advice on the use of PPIs with focus on appropriate prescription and deprescription of PPIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsHelicobacter pyloriGastroesophageal RefluxHumansProton Pump InhibitorsIceland

Stichwörter der Autor:innen

gastringastroesophageal reflux disease (GERD)overutilizationproton pump inhibitors

Substanzen

Proton Pump Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, Haraldsplass Diaconal Hospital, Bergen, Norway, 2Department of Gastroenterology, Haukeland University Hospital - Bergen, Norway.
  • Department of Gastroenterology, Landspítali National University Hospital, Iceland.

Zitieren

APA

Helgadottir, H., & Bjornsson, E. S. (2023). Current use of proton pump inhibitors and when to limit, stop or not start treatment. Læknablaðið, 109(0708), 338-345. https://doi.org/10.17992/lbl.2023.0708.752

Vancouver

Helgadottir H, Bjornsson ES. Current use of proton pump inhibitors and when to limit, stop or not start treatment. Læknablaðið. 2023;109(0708):338-345. doi:10.17992/lbl.2023.0708.752

BibTeX
@article{Helgadottir2023,
  author = {Helgadottir, Holmfridur and Bjornsson, Einar Stefan},
  title = {Current use of proton pump inhibitors and when to limit, stop or not start treatment},
  journal = {Læknablaðið},
  year = {2023},
  volume = {109},
  number = {0708},
  pages = {338--345},
  doi = {10.17992/lbl.2023.0708.752}
}
Kostenlos starten →